Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - September 2013


SMi - Cancer Vaccines

18 Sep 2013 - 19 Sep 2013 - London, UK



Bookmark and Share


SMi proudly presents the 2nd annual conference on Cancer Vaccines taking place on 18th and 19th September, London. This year’s event aims to focus on innovation and novel strategies within the field, the regulatory environment, and the future direction of cancer vaccines; as well as offering current preclinical and clinical outlook, data, and case studies.

As cancer is still one of the greatest causes of human mortality it is a very attractive target for vaccination. Despite a dramatic increase in research within cancer vaccines in the last decade, there is still a need for more effective therapies to maximise cancer survival rates. Novel strategies for target selection, vaccine design, immunostimulatory therapies, and other biologics are constantly being developed and improved.

Cancer Vaccine 2013 will examine not only current clinical data but also the new innovations within the field. This informative event will draw from expert opinions, groundbreaking data, and regulatory factors to look to the future and assess where the field is advancing. This really is a unique event not to be missed.

Benefits of Attending:

Explore innovative and novel strategies, approaches, and vaccines within the field.

Discover future trends, the direction of the field, and combination strategies in both preclinical and clinical situations.

Evaluate the regulatory environment and the subsequent impact on cancer vaccine development.

Consider current trial data, clinical developments, and successful therapeutic vaccines

Learn from successes, failures, and challenges from experts in the field, and apply to optimise vaccine development

Speakers include:

Alex Kudrin, Medical Assessor, Biologicals Licensing, MHRA

Kevin Pollock, Senior Epidemiologist, NHS National Services Scotland

Martin Glennie, Professor of Immunochemistry, University Of Southampton

Pierre van der Bruggen, Group Leader, Ludwig Institute for Cancer Research

Rose-Ann Padua, Research Director, INSERM

Sonia Quaratino, Senior Medical Director and Immunology Advisor, Merck Serono

REGISTER ONLINE AT www.smi-online.co.uk/goto/2013cancervaccinesevent47.asp

For further information, contact Fateja Begum on Tel: +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk



Further information
Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Long-Term Culturing of Adult Stem Cells
A new procedure developed by Harvard Stem Cell Institute researchers (HSCI) at Massachusetts General Hospital (MGH) may revolutionize the culturing of adult stem cells.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Plant-Based Vaccine Among Front Runners In Search For New Polio Jab
A researcher from Norwich is part of a consortium that has been awarded $1.5 million to develop safer polio vaccines, using a new technique developed at the John Innes Centre.
Harnessing Helpful Microbes
Seeking to further harness microbes’ many uses, the federal government has launched the National Microbiome Initiative (NMI) to “foster the integrated study of microbiomes across different ecosystems.”
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Better Animal Model to Improve HIV Vaccine Development
Penn study identifies a new tool to produce better HIV vaccine designs.
First Large-Scale Proteogenomic Study of Breast Cancer
The study offers understanding of potential therapeutic targets.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!